24/7 Wall St. Insights The bull market rally that started in the fall of 2023 may be coming to an end.

“What is a Dividend King? A stock with 50 or more consecutive years of dividend increases.”—suredividend.com. The 53 Dividend Kings, screened as of August 6, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 9.36%-31.67% topped-by PPG, and Target. By yield, Altria tops-all. Top-ten August dogs: NFG, FRT, KVUE, FTS, UBSI, BKH, NWN, CDUAF, UVV, & MO averaged 4.92% in yield.

Johnson & Johnson spun off its consumer segment into Kenvue, a $40 billion company in the consumer defensive sector. Kenvue operates in three main segments, including well-known brands like Tylenol, Neutrogena, and Listerine, with a global sales distribution. Despite recent underperformance, Kenvue saw a 14% stock price rally after reporting 2Q24 earnings, beating market expectations and showing signs of optimism.

Cheap stocks are often cheap for a reason. That bit of investing wisdom underscores the need to perform due diligence on a company and not just buy it because the stock trades at a low price.

Major U.S. equities indexes rebounded on Tuesday following three turbulent days of trading that saw heightened levels of economic uncertainty send stocks tumbling.

Kenvue Inc. (NYSE:KVUE ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Jim Giannakouros - Interim Head, Investor Relations Thibaut Mongon - Chief Executive Officer Paul Ruh - Chief Financial Officer Conference Call Participants Anna Lizzul - BofA Securities, Inc. Steve Powers - Deutsche Bank Securities, Inc. Andrea Teixeira - JPMorgan Securities LLC Nik Modi - RBC Capital Markets LLC Filippo Falorni - Citigroup Global Markets, Inc. Susan Anderson - Canaccord Genuity Jeremy Fialko - HSBC Peter Grom - UBS Operator Hello and welcome to the Kenvue Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.

Kenvue (KVUE) shares surged in intraday trading Tuesday after the company affirmed its full-year guidance that topped analysts' expectations.

Among the key stocks in focus in today's session is Kenvue (NYSE: KVUE ). The company, which was spun off from parent Johnson & Johnson (NYSE: JNJ ) almost exactly one year ago, is seeing strong traction in the market today.

“Dividend Aristocrats

Shares of the Band-Aid parent are on track for their largest daily percent increase on record.

Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Kenvue (KVUE) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago.